CD200R1 and Miyoshi myopathy: Blockade of the CD200-CD200R immune checkpoint using a therapeutic anti-CD200 mAb was hypothesized to restore and/or enhance tumor cell recognition and CTL mediated anti-tumor responses in advanced CLL and MM patients with limited therapeutic options.